Table of Contents Table of Contents
Previous Page  148 / 916 Next Page
Show Menu
Previous Page 148 / 916 Next Page
Page Background


25th European Congress of Psychiatry / European Psychiatry 41S (2017) S106–S169

The next aim was to compare profiles of cognitive impairment in

both groups of patients.

The last aim was to find out a relationship between cognitive per-

formance and severity of depressive episode during the acute state

of illness.


We have used neuropsychological test battery

(Auditory–Verbal Learning Test, Rey-Osterrieth Complex Fig-

ure Test, Logical Memory, Digit span test, Trail making test, Verbal

Fluency Test, Block Design and Benton Visual Retention Test) for

the evaluation of the cognitive functions in patients with severe

depressive episode with psychotic symptoms (


= 5) and patients

with major depressive disorder (


= 8).


We found cognitive impairment in all examined domains

in both groups of patients.

More profound cognitive impairment was found in patients with

severe depressive episode with psychotic symptoms, particu-

larly in visual memory, visuo-constructive abilities, speed of

cognitive processing and executive functions. We found no cor-

relation between cognitive performance and severity of depressive



Our findings suggest a strong correlation between

psychotic symptoms in depression and cognitive performance.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.


Maternal depressive symptom

trajectories and psychosocial

functioning in young adults: A 27-year

longitudinal study

I. Luoma

1 ,

, M. Korhonen


, R. Salmelin



Tampere University Hospital, Child Psychiatry, Tampere, Finland


Helsinki University Hospital, Child Psychiatry, Helsinki, Finland


University of Tampere, School of Health Sciences, Tampere, Finland

Corresponding author.


Maternal depression is a well-known risk factor for

child development. Longitudinal studies extending frompregnancy

to adulthood, however, are rare.


The aim of the study was to investigate whether

maternal high depressive symptom trajectories (chronic or inter-

mittent depressive symptom patterns) from pregnancy to the

adolescence of the children predict lower adaptive functioning

or higher levels of emotional or behavioural symptoms in young



The sample comprised 329 first-time mothers from

maternity centres in Tampere, Finland. Maternal depressive symp-

toms were assessed with the Edinburgh Postnatal Depression Scale

(EPDS) antenatally and at two months, six months, 4–5 years,

8–9 years and 16–17 years after delivery. A model including four

symptom trajectories (very low, low-stable, high-stable and inter-

mittent) was selected to describe the symptom patterns over time.

Adaptive functioning and problems of the children (


= 144) were

assessed by the Adult Self Report forms (Achenbach & Rescorla) at

the age of 27 years.


High maternal depressive symptom trajectories did not

predict self-reported lower adaptive functioning of the children in

adulthood. However, children of mothers with chronic or inter-

mittent depressive symptom patterns reported higher levels of

internalising problems as well as symptoms of depression and anx-

iety in young adulthood than the children of mothers with very low

or low stable symptom patterns.


Highmaternal depressive symptom trajectories pre-

dict higher levels of emotional symptoms of children in young

adulthood. The mechanisms of intergenerational transmission are

important topics for further research.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.


Quetiapine XR as add-on to

antidepressants in

treatment-resistant late-life major


O. Vasiliu

1 ,

, D. Vasile


, D.G. Vasiliu


, A. Andreea Filareta



F. Vasile



“Dr. Carol Davila” Central Military Hospital, Psychiatry, Bucharest,



Coltea Clinical Hospital, Internal Medicine, Bucharest, Romania


University of Medicine and Pharmacy Titu Maiorescu, General

Medicine, Bucharest, Romania

Corresponding author.


To assess the efficacy and tolerability of quetiapine as

add-on to antidepressant agents in treatment-resistant late-life

major depression.


A group of 15 patients, 8 male and 7 female, mean

age 68.2, evaluated in our department for clinical symptoms that

made possible a DSM 5 diagnosis of major depressive disorder,

were initiated on quetiapine XR, flexible daily dose 50–300mg QD.

All patients were on treatment with an antidepressant–either a

selective serotonin reuptake inhibitor (SSRI) (


= 10), or venlafax-

ine (


= 5)–for at least 6 weeks and presented no improvement

during current treatment administered at therapeutic doses.

Patients were assessed using Montgomery Asberg Depression Rat-

ing Scale (MADRS), Clinical Global Impression–Severity (CGI-S),

Global Assessment of Functioning (GAF), and Columbia Suicide

Severity Rating Scale (C-SSRS) every 4 weeks for 3 months.


After 12 weeks, patients had a mean improvement in

MADRS score of 45.7


2.3%, with a final mean MADRS score of 13.5



< 0.01). No variations were registered depending on the specific

SSRI or venlafaxine concomitant treatment. Quetiapine XR mean

daily dose administered during the studywas 125mg. C-SSRS didn’t

registered significant variations in suicidal ideation or behavior

throughout the trial. Overall GAF score increased with 22.1 points,

and CGI-S decreasedwith a mean of 1.5 points at week 12 (


< 0.01).

Tolerability of add-on quetiapine was very good, no serious adverse

event being reported.


Quetiapine was efficient and well tolerated in late-

life resistant major depression, as add-on to SSRIs or venlafaxine,

during the 12 weeks of the trial.

Disclosure of interest

The presenting author was speaker for Bris-

tol Myers Squibb and Servier, and participated in clinical research

funded by Janssen Cilag, Astra Zeneca, Eli Lilly, Sanofi Aventis,

Schering Plough, Organon, Bioline Rx, Forenap, Wyeth, Otsuka

Pharmaceuticals, Dainippon Sumitomo.


The clinical course of depression:

Chronicity is the rule rather than the


J. Verhoeven

, J. Verduijn , Y. Milaneschi , A. Beekman ,

B. Penninx

VU University Medical Center, Psychiatry, Amsterdam, The


Corresponding author.


Major depressive disorder (MDD) is often consid-

ered an episodic disorder. However, literaturemight underestimate

the chronicity of MDD since results depend on follow-up dura-